China court’s positive ruling on the semaglutide patent

Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent.

The drug’s patent holder and marketer, Denmark’s Novo Nordisk (NOV: N), said it is pleased that the Court has upheld the Beijing IP Court ruling recognising the validity of the semaglutide compound patent.

“This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” said Mike Doustdar, president and chief executive of Novo Nordisk. “This decision also strengthens confidence for foreign companies’ sustainable development in China and will motivate further development and introduction of innovative medicines for the benefit of patients,” he noted.